Join
Live feed
·
PRReleasevia Quantisnow
Sonnet BioTherapeutics Holdings Inc. logo

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

ByQuantisnow·Wall Street's wire, on your screen.
SONN· Sonnet BioTherapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SONN (Sonnet BioTherapeutics Holdings Inc.) and more on Quantisnow.